Sanofi SA
SAN
Company Profile
Business description
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
Contact
46, Avenue de la Great Army
Paris75017
FRAT: +33 153774000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
74,846
Stocks News & Analysis
stocks
ASX gold miner under pressure to sell by activist investor
Activist investor presses gold miner on selling to larger players.
stocks
Ask the Analyst: Will Amcor lose its dividend aristocrat status?
When consistency becomes constraint.
stocks
Chart of the Week: We see opportunity in this beaten down industrial player
The market sees risks and are discounting the shares excessively.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,916.90 | 58.60 | -0.65% |
| CAC 40 | 8,246.37 | 95.95 | 1.18% |
| DAX 40 | 24,992.10 | 196.16 | 0.79% |
| Dow JONES (US) | 50,687.07 | 620.72 | -1.21% |
| FTSE 100 | 10,320.72 | 11.58 | -0.11% |
| HKSE | 25,253.40 | 379.81 | -1.48% |
| NASDAQ | 26,853.98 | 239.92 | -0.89% |
| Nikkei 225 | 67,470.69 | 931.45 | -1.36% |
| NZX 50 Index | 13,101.61 | 13.47 | -0.10% |
| S&P 500 | 7,553.68 | 0.00 | 0.00% |
| S&P/ASX 200 | 8,686.10 | 59.50 | -0.68% |
| SSE Composite Index | 4,057.78 | 26.19 | -0.64% |